Acquiring Company
Merck
Acquired Company
Prometheus Biosciences
RahwaySan DiegoManufacturingBiotechnologyHealthcareHealth CareDescription
In May 2023, Merck completed its all-cash acquisition of Prometheus Biosciences for $200.00 per share, valuing the company at approximately $10.8 billion. Following the acquisition, trading of Prometheus shares ceased on the Nasdaq. Merck has fully integrated Prometheus’ precision immunology pipeline into its own portfolio, enhancing its capabilities in treating inflammatory diseases.
Quick answer
Merck is acquiring Prometheus Biosciences for $10.8 billion, announced April 16, 2023. Merck is based in Rahway, New Jersey, United States.
- How much did Merck pay for Prometheus Biosciences?
- The reported deal value is $10.8 billion.
- What does Merck do?
- For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our..
- Where are Merck and Prometheus Biosciences based?
- Merck is based in Rahway, New Jersey, United States. Prometheus Biosciences is based in San Diego, California, United States.
- Who are the decision-makers at Merck?
- Fundz holds 3 contacts at Merck. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Manufacturing
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Shockwave Medical Completes Acquisition Of Neovasc (April 11, 2023)
- Abiogen Pharma Completes The Acquisition Of Effrx (May 29, 2023)
- Medtronic To Acquire Wearable Insulin Patch Maker Eoflow (May 25, 2023)
- Waters Corporation Completes Acquisition Of Light Scattering Leader Wyatt Technology (May 16, 2023)
- Pyxis Oncology To Acquire Apexigen (May 24, 2023)
- Genesis Drug Discovery & Development (Gd3), A Member Of Genesis Global Group, Acquires Jss Medical Research To Expand Its Clinical Services Portfolio (May 10, 2023)
Who to call at Merck, and when
When Merck changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Merck raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Merck, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Merck. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Prometheus Biosciences?
Prometheus Biosciences was acquired by Merck, based in Rahway. The deal was reported on April 16, 2023. Merck is publicly traded (MRK) and operates in Manufacturing.
When did Merck acquire Prometheus Biosciences?
Merck's acquisition of Prometheus Biosciences was reported on April 16, 2023. In May 2023, Merck completed its all-cash acquisition of Prometheus Biosciences for $200.00 per share, valuing the company at approximately $10.8 billion. Following the acquisition, trading of Prometheus shares ceased on the Nasdaq. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Prometheus Biosciences do?
Prometheus Biosciences, Inc. is a privately held biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. It is privately held, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.